Neuroendocrine Tumor Market to Reach $5.3 Billion by 2035

Neuroendocrine tumor (NET) market was valued at $3.2 billion in 2025 and is projected to reach $5.3 billion by 2035, expanding at a CAGR of 5.4%. Rising cancer burden is a key macro driver supporting market expansion. According to the World Health Organization, cancer accounted for nearly 10 million deaths globally in 2022, with an increasing incidence of rare cancers such as neuroendocrine tumors due to improved diagnostics and aging populations. Additionally, the European Federation of Pharmaceutical Industries and Associations highlights a steady rise in oncology R&D investments across Europe. This increased funding is accelerating innovation in targeted therapies and radioligand treatments, thereby strengthening the development pipeline and driving demand for advanced neuroendocrine tumor therapeutics.

Browse the full report description of “Neuroendocrine Tumor Market Size, Share & Trends Analysis Report by Therapy (Somatostatin Analogues (SSAs), Targeted Therapy, Chemotherapy, Peptide Receptor Radionuclide Therapy (PRRT), Immunotherapy, Surgical Therapy), By Indication (Gastrointestinal NETs (GI NETs), Pancreatic NETs (pNETs), Lung NETs, Other Rare NETs), By End-Use Industry (Hospitals, Cancer Specialty Centers, Clinics Care, Academic Research), and Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/neuroendocrine-tumor-market

Leading Players Accelerate Innovation in the Neuroendocrine Tumor Market

The key players in the neuroendocrine tumor market include Novartis AG, Ipsen, Pfizer Inc., Exelixis Inc., and Bayer AG, among others. These companies are advancing NET treatment through innovations in somatostatin analogues, targeted therapies, and radioligand treatments such as PRRT. Their focus remains on improving survival outcomes, expanding indications, and enhancing precision oncology approaches. Additionally, increased investments in oncology R&D and radiopharmaceutical manufacturing are strengthening global treatment accessibility and supporting the evolution of NET care standards.

• In October 2025, Exelixis Inc. announced subgroup analysis results from the phase III CABINET trial, showing that cabozantinib demonstrated consistent benefit across multiple neuroendocrine tumor patient subgroups, including both pancreatic and extra?pancreatic NETs. These findings support broader clinical utility and reinforce cabozantinib’s role as a meaningful treatment option in previously treated advanced NETs.

• In March 2025, Novartis AG received FDA approval for its radioligand therapy Pluvicto for earlier use in patients with PSMA-positive metastatic castration-resistant prostate cancer. The approval allows treatment prior to chemotherapy, expanding patient eligibility and reinforcing the growing role of targeted radioligand therapies in oncology.

Market Coverage

• The market number available for – 2025–2035
• Base year- 2025
• Forecast period- 2026–2035
• Segment Covered-
• By Therapy
• By Indication
• By End-User Industry
• Regions Covered-
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Competitive Landscape: Novartis AG, Ipsen, Pfizer Inc., Exelixis Inc., Bayer AG, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Neuroendocrine Tumor Market Report Segment

By Therapy

• Somatostatin Analogues (SSAs)
• Targeted Therapy
• Chemotherapy
• Peptide Receptor Radionuclide Therapy (PRRT)
• Immunotherapy
• Surgical Therapy

By Indication

• Gastrointestinal NETs (GI NETs)
• Pancreatic NETs (pNETs)
• Lung NETs
• Other Rare NETs

By End-Use Industry

• Hospitals
• Cancer Specialty Centers
• Clinics Care
• Academic Research

Global Neuroendocrine Tumor Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/neuroendocrine-tumor-market